RESUMO
Objective To investigate the clinical efficacy and toxicity of bevacizumab combined with chemotherapy in elderly patients with gastrointestinal neoplasms.Methods A total of 64 elderly patients with gastrointestinal neoplasms were selected.The clinical data of patients treated with chemotherapy or chemotherapy plus bevacizumab were analyzed.Patients were randomly divided into the observation group and the control group (n=32,each).The observation group was treated with bevacizumab (7.5 mg/kg) in combination with XELOX (OXA+Xeloda),and the control group was treated with XELOX only (21 weeks as a cycle).The clinical efficacy and toxicity of bevacizumab were evaluated according to WHO short-term efficacy standards and standards of anticancer drugs in acute or subacute adverse reactions.Results In observation group,complete remission was found in 4 cases,partial response in 18 cases,stable disease in 6 cases,progressive disease in 4 cases,and the total efficiency was 68.8％.In control group,partial response was found in 14 cases,stable disease in 11 cases,progressive disease in 7 cases,and the total efficiency was 43.8％.The incidences of leucopenia,hemoglobin desaturation and gastrointestinal reactions were lower and the incidence of thrombocytopenia was higher in observation group than in control group,which had no significant differences between the 2 groups.Phase Ⅳ toxicity was not found in observation group.Conclusions Bevacizumab combined with chemotherapy is safe and effective for elderly patients with gastrointestinal neoplasms.Most patients can tolerate the side effects.It is worth promoting in clinical medicine.
RESUMO
AIM: To investigate the expression of drug resistance genes, MDR1 and MRP, in patients with primary breast cancer after neoadjuvant chemotherapy. METHODS: MDR1 and MRP gene expression were detected by semi-quantitative RT-PCR in 20 patients with primary breast cancer before and after chemotherapy. RESULTS: Before chemotherapy, MDR1 and MRP expression could be detected in 15 cases (75%) and 18 cases (90%), respectively. After chemotherapy, expression of MDR1 was not significantly different from that before chemotherapy, but expression of MRP was significantly different from that before chemotherapy. CONCLUSION: Drug resistance gene MRP, but not MDR1 expression is enhanced in patients with primary breast cancer subjected to neoadjuvant chemotherapy.
RESUMO
AIM: To investigate antitumor immune response induced by Dendritic cells (DCs) pulsed with antigen MAGE-3. METHODS: DCs were obtained from peripheral blood mononuclear cells induced with granulocyte/macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), tumor necrosis factor-?(TNF-?), and pulsed with antigen MAGE-3. After cocultured with DCs for 7 days, T cells were collected and special CTLs were studied. RESULTS: T cells cocultured with MAGE-3 antigen pulsed DCs effectively killed the MAGE-3 positive MKN-45 tumor cells in vitro . CONCLUSION: DCs pulsed with MAGE-3 are able to present antigen effectively, activate antigen-specific CTLs and induce special antitumor immune response in vitro.
RESUMO
AIM: To investigate the expression of angiopoietin-Ⅱ(Ang-Ⅱ)in primary gastric cancer and the pathological factors that influences it. METHODS: Expression of Ang-Ⅱ and VEGF were studied in 72 primary gastric cancer and adjacent normal tissue by reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry. RESULTS: The significant difference of Ang-Ⅱ expression between primary tumor and adjacent normal tissue samples was observed. The correlationship between Ang-Ⅱ and VEGF expression in tumors was statistically significant. The expression of Ang-Ⅱ was related to tumor stage and vascular involvement. CONCLUSION: The results manifested that Ang-Ⅱ may play a role in regulating tumor angiogenesis.
RESUMO
AIM: To construct pcDNA3.1+/MAGE-3 DNA vaccine and investigate the antigen-specific antitumor immune responses induced by pcDNA3.1+/MAGE-3 DNA vaccine in vivo. METHODS: C57BL/6 mice challenged with B16/MAGE-3 cells were immunized by intramuscular injection of pcDNA3.1+/MAGE-3 DNA vaccine every 10 days. pcDNA3.1+ plasmid and PBS were used as controls. After three cycles of immunization, murine splenic lymphocytes, serum, and tumor were obtained for cytotoxity assay, detections of cytokines (IL-2 and IFN-?), measurement of MAGE-3 antibody, and tumor inhibitory rates, respectively. RESULTS: The pcDNA3.1+/MAGE-3 DNA vaccine immunized murine lymphocytes induced specific cytotoxicity against B16/MAGE-3 cells. Significantly increased secretions of IL-2 and IFN-? were detected. The titres of antibody against MAGE-3 were 1∶1 and 1∶20, while controls were negative. The tumor inhibitory rate in pcDNA3.1+/MAGE-3 group was significantly different from that in controls. CONCLUSION: The pcDNA3.1+/MAGE-3 DNA vaccine was constructed successfully. pcDNA3.1+/MAGE-3 DNA vaccine activates both cellular and humoral immune responses, and induces antigen-specific antitumor immune responses in vivo. [